Vietnam Generic Drugs Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2025)

USD 3.57 Billion

Market (2034)

USD 8.65 Billion

CAGR

10.34%

Major Markets Players

DHG Pharmaceutical Joint Stock Company, Traphaco Joint Stock Company, Pymepharco Joint Stock Company, Hatay Pharmaceutical Joint Stock Company, Mekophar Chemical Pharmaceutical JSC and Others

*Note: Partial List Randomly Ordered

Vietnam Generic Drugs Market Statistics and Insights

Vietnam Generic Drugs Market Insights & Analysis

The Vietnam Generic Drugs Market is anticipated to register a 10.34% CAGR during 2026–2034. The market size was valued at USD 3.57 billion in 2025 and is projected to reach USD 8.65 billion by 2034. Vietnam's generic pharmaceutical landscape is undergoing a structural transformation fueled by a confluence of demographic momentum, rising chronic disease burden, and deliberate government intervention. The Ministry of Health's National Pharmaceutical Industry Development Strategy (to 2030 and Vision to 2045) mandates that locally produced medicines meet at least 80% of domestic demand, directly accelerating generic drug production.

Foreign direct investment into Vietnam's healthcare and pharmaceutical sectors reached USD 13.82 billion in early 2025, representing a near 40% year-on-year surge, a portion of which is channeling into generic manufacturing infrastructure. Additionally, the government's target of achieving 95% universal health insurance coverage by 2025 is significantly expanding the patient base for affordable generic therapies. With approximately seven million citizens living with diabetes and cardiovascular conditions accounting for over 100,000 deaths annually, the demand pipeline for cost-accessible generic medicines is both vast and sustained.

Vietnam Generic Drugs Market Dynamics

Key Market Driver: Universal Health Coverage Accelerating Generic Demand

Vietnam's aggressive push toward universal healthcare is a structural pillar underpinning generic drug demand. The government's health insurance framework, which now covers over 93% of the population, mandates the procurement of generic medicines in public hospital tenders under the timelimited bidding group system. This policy compels hospitals to prioritize domestically manufactured generics, dramatically expanding market volume. As of 2024, domestically produced medicines represented approximately 49% of total pharmaceutical value consumed within the country. With the amended Pharmacy Law (effective July 2025) further streamlining drug registration timelines and incentivizing local Good Manufacturing Practice (GMP) compliance upgrades, Vietnamese manufacturers are scaling production capacity at a record pace to capitalize on guaranteed public procurement pathways.

Major Industry Challenge: API Import Dependency Disrupts Supply Chains

One of the most persistent structural vulnerabilities within Vietnam's generic drugs sector is its heavy reliance on imported active pharmaceutical ingredients (APIs). An estimated 80–90% of raw materials for domestic generic drug production are sourced from China and India, creating pronounced supply chain fragility. Geopolitical disruptions, port congestion, or regulatory shifts in exporting nations can result in production halts, drug shortages, and pricing volatility that disproportionately affect cost-sensitive generic segments. Vietnam currently lacks a domestic API manufacturing ecosystem of sufficient scale to replace this dependency in the near term. While the government has identified API self-sufficiency as a strategic priority under its 2030 pharmaceutical roadmap, establishing competitive API production capacity requires multi-year capital investments and specialized technical expertise that remain scarce within the domestic industry.

Emerging Trend Shaping Outlook: Digital Pharmacies Reshaping Generic Distribution Landscape

The rapid proliferation of e-pharmacy platforms is fundamentally restructuring how generic drugs reach Vietnamese consumers. Platforms integrating telemedicine consultations, e-prescriptions, and home delivery of generic medicines are gaining measurable traction, particularly in urban centers such as Ho Chi Minh City and Hanoi. This distribution shift is lowering last-mile costs, increasing generic drug accessibility in peri-urban zones, and enabling real-time inventory management among domestic manufacturers. Major pharmacy chains are accelerating digital integration, while standalone online pharmacies are attracting venture capital interest. The Ministry of Health's progressive stance on e-prescription legalization is expected to formally legitimize this channel, unlocking significant incremental volume for generic products across chronic disease categories such as diabetes, hypertension, and oncology-support therapies.

Vietnam Generic Drugs Market Segment-wise Analysis

Vietnam's generic drug market exhibits distinct demand characteristics across its distribution and therapeutic application dimensions. The interplay between government procurement mandates, evolving retail pharmacy infrastructure, and the country's shifting disease burden creates differentiated growth trajectories across each segment. Understanding these nuances is essential for manufacturers, investors, and healthcare policymakers navigating this high-growth Southeast Asian market.

By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Others

The Retail Pharmacies sub-segment commands the dominant share of the Vietnam Generic Drugs Market, accounting for approximately 48% of total revenue in 2025. Vietnam's retail pharmacy network is extensive, comprising over 62,000 licensed retail agents operating across urban and rural geographies, providing a robust and deeply embedded distribution infrastructure for generic medicines. The accessibility and convenience of community pharmacies, combined with the price sensitivity of Vietnamese consumers, makes retail channels the preferred point of dispensing for a wide range of generics spanning antibiotics, cardiovascular medications, and antidiabetic drugs.

Hospital Pharmacies constitute the second-largest distribution channel, capturing roughly 31% of market revenue, driven by mandated generic procurement policies in public hospital tendering systems. Online Pharmacies, while currently representing approximately 9% of distribution value, are the fastest-growing sub-segment, propelled by e-prescription adoption and expanding digital health platforms. The Others category, encompassing government health posts and institutional channels, accounts for the remaining share.

By Application

• Neurology
• Oncology
• Cardiovascular Diseases
• Diabetes
• Anti-Inflammatory Diseases
• Others

The Cardiovascular Diseases sub-segment leads the application landscape, accounting for approximately 27% of Vietnam Generic Drugs Market revenue in 2025. Cardiovascular conditions are the leading cause of mortality in Vietnam, responsible for over 100,000 deaths annually and affecting approximately 1.6 million individuals across the country, creating a structurally elevated demand base for affordable antihypertensive, anticoagulant, and lipid-lowering generic medicines.

Diabetes follows as a major revenue contributor at approximately 21%, with Vietnam's diabetic population estimated at seven million and growing, more than 55% of whom already present with complications. Oncology generics are gaining rapid traction as Vietnam records approximately 165,000 new cancer cases annually, making supportive and adjuvant generic therapies increasingly important. Neurology and Anti-Inflammatory Diseases collectively contribute the remaining meaningful share, driven by rising stroke incidence and musculoskeletal disease prevalence across the aging demographic.

Regional Projection of Vietnam Generic Drugs Market

Vietnam's generic drug demand is geographically concentrated, with distinct urban-rural disparities shaping consumption patterns:

• Southern Vietnam
• Northern Vietnam
• Central Vietnam

Southern Vietnam, anchored by Ho Chi Minh City, is the leading region in the Vietnam Generic Drugs Market, commanding approximately 39% of total market revenue. The region's dominance is attributed to its dense private hospital infrastructure, the highest per capita pharmaceutical spending in the country, and the concentration of major domestic generic manufacturers including DHG Pharmaceutical and Mekophar. Ho Chi Minh City's advanced retail pharmacy network and early adoption of digital health platforms further accelerate generic drug consumption in this region. Northern Vietnam, centered on Hanoi, is the second-largest region, benefiting from strong government procurement volumes and the presence of leading manufacturers such as Traphaco.

Vietnam Generic Drugs Market: Recent Development (2025)

• DHG Pharmaceutical reported a 14% revenue increase in Q1 2025, driven by expanded generic cardiovascular portfolio.
• Traphaco JSC posted a net profit margin of 11.3% in fiscal 2025, aided by new oncology generic formulations launched.
• Pymepharco Joint Stock Company secured EU-GMP certification for two additional production lines in early 2025.
• Imexpharm Corporation signed a strategic technology transfer agreement with a South Korean API supplier in March 2025.

Vietnam Generic Drugs Market Future Outlook (2034)

The Vietnam Generic Drugs Market is poised for sustained high-trajectory growth, projected to reach USD 8.65 billion by 2034 at a CAGR of 10.34% during 2026–2034. Growth will be increasingly propelled by Vietnam's expanding health insurance framework, the government's domestic API development initiative under its 2030 pharmaceutical strategy, and the accelerating integration of AI-driven drug discovery and quality control processes within domestic manufacturing facilities. Manufacturers investing in EU-GMP and WHO-GMP compliance will unlock export opportunities to regulated markets in Europe and ASEAN, diversifying revenue streams beyond domestic demand. The convergence of an aging population, a growing chronic disease burden, and digitally empowered distribution channels positions Vietnam's generic drug sector as one of the most compelling pharmaceutical growth stories in Southeast Asia through 2034.

Why Choose This Report?

• Provides a comprehensive overview of the overall market analysis, encompassing key trends, consumer behavior analysis, and risk assessment to support strategic decision-making.
• Provides accurate, up-to-date insights into market size, segmentation, and emerging opportunities, helping to minimize risk & capitalizing on growth.
• Gives deep understanding of target audience preferences, investment habits, and communication channels for enhanced product development & marketing effectiveness.
• Delivers competitive analysis & benchmarking, uncovering the strengths & weaknesses of market competitors to guide strategies.
• Consolidate comprehensive market intelligence, reducing reasoning & streamlining research efforts.
• Facilitates customized market segmentation & risk mitigation strategies, fine-tuned to the business objectives.
• Aids in identifying both market challenges & untapped opportunities within the industry to drive long-term business growth.
• Provides valuable information based on actual customer data & search trends.